source
- Acadia misses mark in Alzheimer’s but concludes phase 3 ‘absolutely worth’ pursuingAcadia Pharmaceuticals’ phase 2 Alzheimer’s disease trial has missed its primary endpoint, but the company and analysts alike saw enough encouraging signals to support the continuation of a phase 3…
- Roche signs up to $2 billion partnership with Atavistik to develop cardiometabolic drugsRoche announced a partnership with Atavistik Bio, a biotech focused on hematology, to pursue new small-molecule treatments for cardiovascular, renal and metabolic conditions. The agreement provide…